{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:59:18Z","timestamp":1790891958989,"version":"4.1.0"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bulcan.2026.08.004","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:30:35Z","timestamp":1790890235000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Indications du chim\u00e9risme sur cellules tri\u00e9es apr\u00e8s allogreffe de cellules souches h\u00e9matopo\u00ef\u00e9tiques (SFGM-TC)"],"prefix":"10.1016","author":[{"given":"Debora","family":"Jorge-Cordeiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Cargou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Crocchiolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"El-Cheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Ferru-Clement","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Filloux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Geurten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Guillaume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambroise","family":"Marcais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moskovtchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibault","family":"Pajot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flore","family":"Sicre De Fontbrune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9gane","family":"Tanguay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie","family":"Toullec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Villemonteix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali\u00e9nor","family":"Xhaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9onardo","family":"Magro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9299-3705","authenticated-orcid":false,"given":"Pascal","family":"Pedini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2026.08.004_bib0370","doi-asserted-by":"crossref","first-page":"1023116","DOI":"10.3389\/fimmu.2023.1023116","article-title":"New methods for the quantification of mixed chimerism in transplantation","volume":"14","author":"Picard","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0375","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41409-022-01579-9","article-title":"Chimerism analysis for clinicians: a review of the literature and worldwide practices","volume":"57","author":"Blouin","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0380","doi-asserted-by":"crossref","first-page":"4618","DOI":"10.1182\/blood.V99.12.4618","article-title":"Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction","volume":"99","author":"Alizadeh","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0385","doi-asserted-by":"crossref","first-page":"102","DOI":"10.4161\/chim.25400","article-title":"Detection and quantification of chimerism by droplet digital PCR","volume":"4","author":"George","year":"2013","journal-title":"Chimerism"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0390","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.exphem.2015.02.006","article-title":"Digital PCR to assess hematopoietic chimerism after allogeneic stem cell transplantation","volume":"43","author":"Stahl","year":"2015","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0395","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.3892\/mmr.2016.5593","article-title":"A technical application of quantitative next generation sequencing for chimerism evaluation","volume":"14","author":"Aloisio","year":"2016","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0400","doi-asserted-by":"crossref","first-page":"e70770","DOI":"10.1111\/tan.70770","article-title":"Third-generation nanopore sequencing for post-transplant chimerism monitoring","volume":"107","author":"Pedini","year":"2026","journal-title":"HLA"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0405","first-page":"267","article-title":"Chimerism testing in myeloid malignancies: techniques, considerations, and connections to post-transplant outcomes","volume":"57","author":"Puzo","year":"2025","journal-title":"Pathology (Phila)"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0410","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/j.bulcan.2017.08.010","article-title":"\u00c9tude du chim\u00e9risme apr\u00e8s allogreffe de cellules h\u00e9matopo\u00ef\u00e9tiques: recommandations de la Soci\u00e9t\u00e9 francophone de greffe de moelle et de th\u00e9rapie cellulaire (SFGM-TC)","volume":"104","author":"Dubois","year":"2017","journal-title":"Bull Cancer (Paris)"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0415","first-page":"bjh.70061","author":"Clark","year":"2025","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0420","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.humimm.2021.07.013","article-title":"A practical guide to chimerism analysis: review of the literature and testing practices worldwide","volume":"82","author":"Blouin","year":"2021","journal-title":"Hum Immunol"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0425","doi-asserted-by":"crossref","first-page":"993","DOI":"10.3390\/cells13110993","article-title":"Prospects and potential for chimerism analysis after allogeneic hematopoietic stem cell transplantation","volume":"13","author":"Miura","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0430","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1080\/17843286.2020.1754635","article-title":"Use of chimerism analysis after allogeneic stem cell transplantation: Belgian guidelines and review of the current literature","volume":"76","author":"Delie","year":"2021","journal-title":"Acta Clin Belg"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0435","doi-asserted-by":"crossref","first-page":"841608","DOI":"10.3389\/fonc.2022.841608","article-title":"Analysis of subset chimerism for MRD-Detection and pre-emptive treatment in AML","volume":"12","author":"Georgi","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0440","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1016\/j.bulcan.2016.09.006","article-title":"Ateliers d\u2019harmonisation des pratiques de la SFGM-TC","volume":"103","author":"Tipton","year":"2016","journal-title":"Bull Cancer (Paris)"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0445","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.leukres.2014.02.001","article-title":"Role of minimal residual disease and chimerism after reduced-intensity and myeloablative allo-transplantation in acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"38","author":"Bernal","year":"2014","journal-title":"Leuk Res"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0450","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1038\/s41375-019-0624-4","article-title":"Quantitative chimerism in CD3-negative mononuclear cells predicts prognosis in acute myeloid leukemia patients after hematopoietic stem cell transplantation","volume":"34","author":"Bouvier","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0455","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1200\/JCO.20.02308","article-title":"Augmented reduced-intensity regimen does not improve postallogeneic transplant outcomes in acute myeloid leukemia","volume":"39","author":"Craddock","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0460","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1200\/JCO.2015.62.7273","volume":"33","author":"Devine","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0465","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/ejh.13772","article-title":"Mixed T cell CHIMERISM in bone marrow at day+30\u00a0after allogeneic stem cell transplantation: Correlation with acute GVHD grades III-IV and no impact on relapse and overall survival","volume":"109","author":"Guidotti","year":"2022","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0470","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/j.bbmt.2015.07.005","article-title":"Mixed T lymphocyte chimerism after allogeneic hematopoietic transplantation is predictive for relapse of acute myeloid leukemia and myelodysplastic syndromes","volume":"21","author":"Lee","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0475","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1182\/bloodadvances.2022009493","article-title":"Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML\/MDS","volume":"7","author":"Loke","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0480","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1080\/10428194.2020.1827249","article-title":"Does early chimerism testing predict outcomes after allogeneic hematopoietic stem cell transplantation?","volume":"62","author":"Mountjoy","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0485","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.bbmt.2017.01.086","article-title":"Prognostic limitations of donor T cell chimerism after myeloablative allogeneic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"23","author":"Wong","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0490","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/bmt.2016.323","article-title":"Impact of T-cell chimerism on relapse after cord blood transplantation for hematological malignancies: Nagoya Blood and Marrow Transplantation Group study","volume":"52","author":"Yokohata","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0495","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/leu.2010.283","article-title":"Monitoring of WT1\u00a0expression in PB and CD34+ donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning","volume":"25","author":"Lange","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0500","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/bmt.2013.2","article-title":"CD34(+) lineage specific donor cell chimerism for the diagnosis and treatment of impending relapse of AML or myelodysplastic syndrome after allo-SCT","volume":"48","author":"Rosenow","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0505","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00277-013-1961-4","article-title":"Monitoring of acute myeloid leukemia patients after allogeneic stem cell transplantation employing semi-automated CD34+ donor cell chimerism analysis","volume":"93","author":"Hoffmann","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0510","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.leukres.2018.10.007","article-title":"CD34+ chimerism analysis for minimal residual disease monitoring after allogeneic hematopoietic cell transplantation","volume":"74","author":"Unnikrishnan","year":"2018","journal-title":"Leuk Res"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0515","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1038\/s41409-022-01747-x","article-title":"Impact on outcomes of mixed chimerism of bone marrow CD34+ sorted cells after matched or haploidentical allogeneic stem cell transplantation for myeloid malignancies","volume":"57","author":"Le Bris","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0520","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3324\/haematol.2015.135137","article-title":"Risk assessment of relapse by lineage-specific monitoring of chimerism in children undergoing allogeneic stem cell transplantation for acute lymphoblastic leukemia","volume":"101","author":"Preuner","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0525","doi-asserted-by":"crossref","first-page":"454.e1","DOI":"10.1016\/j.jtct.2023.03.025","article-title":"Peripheral blood CD34\u00a0donor chimerism has greater clinical utility than CD3\u00a0for detecting relapse after allogeneic stem cell transplantation for acute myeloid leukemia or myelodysplastic syndrome","volume":"29","author":"Das","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0530","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/s41409-022-01615-8","article-title":"Lineage-specific early complete donor chimerism and risk of relapse after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia","volume":"57","author":"Lindahl","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0535","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1002\/jha2.568","article-title":"Early relapse prediction after allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia (ALL) using lineage-specific chimerism analysis","volume":"3","author":"Lindahl","year":"2022","journal-title":"EJHaem"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0540","doi-asserted-by":"crossref","first-page":"670.e1","DOI":"10.1016\/j.jtct.2025.05.006","article-title":"Comparison of chimerism kinetics and associated outcomes in patients receiving post-transplant cyclophosphamide versus methotrexate based GVHD prophylaxis following allogeneic hematopoietic cell transplant","volume":"31","author":"Baranwal","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0545","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/j.bbmt.2020.07.013","article-title":"Early mixed lymphoid donor\/host chimerism is associated with improved transplant outcome in patients with primary or secondary myelofibrosis","volume":"26","author":"Deeg","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0550","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.3324\/haematol.2019.223503","article-title":"Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation","volume":"106","author":"Samer","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0555","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41408-020-0302-9","article-title":"Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis","volume":"10","author":"Jain","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0560","doi-asserted-by":"crossref","first-page":"780.e1","DOI":"10.1016\/j.jtct.2021.05.020","article-title":"Donor-host lineage-specific chimerism monitoring and analysis in pediatric patients following allogeneic stem cell transplantation: influence of pre-transplantation variables and correlation with post-transplant outcomes","volume":"27","author":"Llaurador","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0565","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/j.bulcan.2018.10.002","article-title":"Injections de lymphocytes du donneur (DLI): recommandations de la Soci\u00e9t\u00e9 francophone de greffe de moelle et de th\u00e9rapie cellulaire (SFGM-TC)","volume":"106","author":"De Vos","year":"2019","journal-title":"Bull Cancer (Paris)"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0570","doi-asserted-by":"crossref","first-page":"183.e1","DOI":"10.1016\/j.jtct.2022.01.022","article-title":"Outcomes after donor lymphocyte infusion in patients with hematological malignancies: donor characteristics matter","volume":"28","author":"Ros-Soto","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0575","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41409-019-0695-x","article-title":"Full donor chimerism without graft-versus-host disease: the key factor for maximum benefit of pre-emptive donor lymphocyte infusions (pDLI)","volume":"55","author":"Feliu","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0580","doi-asserted-by":"crossref","first-page":"e852","DOI":"10.1016\/j.clml.2024.07.006","volume":"24","author":"Tan","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0585","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1016\/j.bbmt.2014.07.003","article-title":"Early donor chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reduced-intensity conditioning","volume":"20","author":"Reshef","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0590","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.bbmt.2014.05.025","article-title":"Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survival","volume":"20","author":"Koreth","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0595","doi-asserted-by":"crossref","first-page":"106173","DOI":"10.1016\/j.leukres.2019.106173","article-title":"Very early lineage-specific chimerism after reduced intensity stem cell transplantation is highly predictive of clinical outcome for patients with myeloid disease","volume":"83","author":"Kinsella","year":"2019","journal-title":"Leuk Res"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0600","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/tan.14557","article-title":"Utility of assessing CD3+ cell chimerism within the first months after allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia","volume":"100","author":"Bendjelloul","year":"2022","journal-title":"HLA"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0605","doi-asserted-by":"crossref","first-page":"1382099","DOI":"10.3389\/fimmu.2024.1382099","article-title":"The predictive value of T-cell chimerism for disease relapse after allogeneic hematopoietic stem cell transplantation","volume":"15","author":"Li","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0610","doi-asserted-by":"crossref","first-page":"77.e1","DOI":"10.1016\/j.jtct.2024.11.006","article-title":"Early mixed donor chimerism is a strong negative prognostic indicator in allogeneic stem cell transplant for AML and MDS","volume":"31","author":"Radford","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0615","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/j.1365-2141.2008.07533.x","volume":"144","author":"Lawler","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0620","doi-asserted-by":"crossref","first-page":"e14160","DOI":"10.1111\/ctr.14160","article-title":"The incidence, clinical outcome, and protective factors of mixed chimerism following hematopoietic stem cell transplantation for severe aplastic anemia","volume":"35","author":"Xu","year":"2021","journal-title":"Clin Transplant"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0625","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.bbmt.2016.11.003","article-title":"Mixed T cell chimerism after allogeneic hematopoietic stem cell transplantation for severe aplastic anemia using an alemtuzumab-containing regimen is shaped by persistence of recipient CD8T cells","volume":"23","author":"Grimaldi","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0630","doi-asserted-by":"crossref","first-page":"257.e1","DOI":"10.1016\/j.jtct.2020.11.024","article-title":"Does mixed chimerism after allogeneic hematopoietic cell transplantation in pediatric patients with fanconi anemia impact on outcome?","volume":"27","author":"Ayas","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0635","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/j.jcyt.2025.07.003","article-title":"Donor T-cell and myeloid chimerism is higher after cord blood transplant than with other cell sources","volume":"27","author":"Nadaf","year":"2025","journal-title":"Cytotherapy"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0640","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.bbmt.2017.08.038","article-title":"Relationship between mixed donor-recipient chimerism and disease recurrence after hematopoietic cell transplantation for sickle cell disease","volume":"23","author":"Abraham","year":"2017","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0645","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.2014.7192","article-title":"Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype","volume":"312","author":"Hsieh","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0650","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/ajh.24183","article-title":"Successful matched sibling donor marrow transplantation following reduced intensity conditioning in children with hemoglobinopathies","volume":"90","author":"King","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0655","first-page":"143","article-title":"Relationship between mixed chimerism and rejection after bone marrow transplantation in thalassaemia","volume":"6","author":"Andreani","year":"2008","journal-title":"Blood Transfus Trasfus Sangue"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0660","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3324\/haematol.2018.213207","article-title":"Long-term event-free survival, chimerism and fertility outcomes in 234\u00a0patients with sickle-cell anemia younger than 30\u00a0years after myeloablative conditioning and matched-sibling transplantation in France","volume":"105","author":"Bernaudin","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0665","doi-asserted-by":"crossref","first-page":"103556","DOI":"10.1016\/j.transci.2022.103556","article-title":"Transfusion support for patients with sickle cell disease","volume":"61","author":"Wallace","year":"2022","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0670","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.3324\/haematol.2019.227561","article-title":"Extensive multilineage analysis in patients with mixed chimerism after allogeneic transplantation for sickle cell disease: insight into hematopoiesis and engraftment thresholds for gene therapy","volume":"105","author":"Magnani","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0675","doi-asserted-by":"crossref","first-page":"1055497","DOI":"10.3389\/fimmu.2022.1055497","article-title":"Donor chimerism and immune reconstitution following haploidentical transplantation in sickle cell disease","volume":"13","author":"Chu","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0680","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1002\/ajh.26599","article-title":"Assessment of donor cell engraftment after hematopoietic stem cell transplantation for sickle cell disease: a review of current and future methods","volume":"97","author":"Lewis","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0685","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1182\/blood-2018-03-840702","article-title":"SCID genotype and 6-month posttransplant CD4\u00a0count predict survival and immune recovery","volume":"132","author":"Haddad","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0690","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.jaci.2016.01.053","article-title":"Effect of stem cell source on long-term chimerism and event-free survival in children with primary immunodeficiency disorders after fludarabine and melphalan conditioning regimen","volume":"138","author":"Rao","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0695","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/bjh.18190","article-title":"The significance of mixed chimaerism and cell lineage chimaerism monitoring in paediatric patients post haematopoietic stem cell transplant","volume":"198","author":"Kricke","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0700","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s10875-023-01612-6","article-title":"Isolated full donor T-Cell chimerism after haploidentical TCR\u03b1\u03b2\/CD19\u00a0depleted HSCT maintains remission of familial HLH","volume":"44","author":"Consonni","year":"2023","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0705","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1182\/bloodadvances.2025017662","article-title":"Hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report","volume":"10","author":"Alexander","year":"2026","journal-title":"Blood Adv"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0710","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1182\/blood-2007-03-076679","article-title":"Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation","volume":"111","author":"Ozsahin","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0715","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood-2010-11-319376","article-title":"Long-term outcome and lineage-specific chimerism in 194\u00a0patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study","volume":"118","author":"Moratto","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0720","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1182\/blood.2019002939","article-title":"Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report","volume":"135","author":"Burroughs","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0725","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1038\/bmt.2012.31","article-title":"Outcomes following hematopoietic cell transplantation for Wiskott\u2013Aldrich syndrome","volume":"47","author":"Shin","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bulcan.2026.08.004_bib0730","doi-asserted-by":"crossref","first-page":"569381","DOI":"10.3389\/fimmu.2020.569381","article-title":"Viral infections in HSCT: detection, monitoring, clinical management, and immunologic implications","volume":"11","author":"Annaloro","year":"2021","journal-title":"Front Immunol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455126004030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455126004030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:30:42Z","timestamp":1790890242000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455126004030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":73,"alternative-id":["S0007455126004030"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.08.004","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Indications du chim\u00e9risme sur cellules tri\u00e9es apr\u00e8s allogreffe de cellules souches h\u00e9matopo\u00ef\u00e9tiques (SFGM-TC)","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}